Management of Side Effects Associated with Endocrine Therapy; Use of Bisphosphonates
Approximately what percent of your patients who receive aromatase inhibitors (AIs) develop arthralgias?
In general, do you continue an aromatase inhibitor (AI) in a patient who is completing the fifth year of an adjuvant AI and is tolerating it well?
A sexually active 70-year-old woman is receiving adjuvant anastrozole after adjuvant chemotherapy/ trastuzumab for ER-positive, HER2-positive breast cancer. She is experiencing vaginal dryness, dyspareunia and frequent urinary tract infections, with no relief from long-acting vaginal moisturizers and lubricants. Her gynecologist prescribed intravaginal estrogen tablets.
A sexually active 70-year-old woman is receiving adjuvant anastrozole after adjuvant chemotherapy/ trastuzumab for ER-positive, HER2-positive breast cancer. She is experiencing vaginal dryness, dyspareunia and frequent urinary tract infections, with no relief from long-acting vaginal moisturizers and lubricants. Her gynecologist prescribed intravaginal estrogen tablets.
A 65-year-old woman with ER-positive, HER2-negative breast cancer is ready to begin anastrozole following chemotherapy. Baseline bone mineral density after completing the chemotherapy shows osteopenia with a T-score of -1.9. The patient exercises and has been receiving calcium and vitamin D supplements and has no other risk factors for osteoporosis.
A patient with metastatic cancer in the bone is responding to anticancer treatment and monthly zoledronic acid (ZA) infusions and is expected to live for more than 2 years.
In general, when starting a patient with metastatic disease on an intravenous bisphosphonate, do you first have the patient go to a dentist or oral surgeon for an initial evaluation?
